Postmenopausal hypertension

Current Hypertension Reports

Volumn 2, Issue 2, 2000, Pages 202-207

  Harrison Bernard, Lisa M ^a   Raij, Leopoldo ^b  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; NITRIC OXIDE;

AGE; ANIMAL; DRUG EFFECT; FEMALE; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; POSTMENOPAUSE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SEX DIFFERENCE;

AGE FACTORS; ANIMALS; ESTROGENS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NITRIC OXIDE; POSTMENOPAUSE; RENIN-ANGIOTENSIN SYSTEM; SEX FACTORS;

EID: 0034166363     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-000-0083-2     Document Type: Article

References (52)

1. Glendy RE, Levine SA, White PD: Coronary disease in youth. JAMA 1937, 109: 1775-1781.
2. Mosca L, Manson JE, Sutherland SE, et al.: Cardiovascular disease in women: a statement for healthcare professionals from the American Heart Association Writing Group. Circulation 1997, 96: 2468-2482.
3. Kannel WB, Wilson PW: Risk factors that attenuate the female coronary disease advantage. Arch Intern Med 1995, 155: 57-61.
4. Sullivan JM, Fowlkes LP: The clinical aspects of estrogen and the cardiovascular system. Obstet Gynecol 1996, 87: 36S-43S.
5. Kannel WB, Hjortland MC, McNamara PM, et al.: Menopause and risk of cardiovascular disease: The Framingham Study. Ann Intern Med 1976, 85: 447-452.
6. Stampfer MJ, Colditz GA, Willett WC, et al.: Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the Nurses' Health Study. N Engl J Med 1991, 325: 756-762.
7. Pines A, Mijatovic V, van der Mooren MJ, et al.: Hormone replacement therapy and cardioprotection: basic concepts and clinical considerations. Eur J Obstet Gynecol Reprod Biol 1997, 71: 193-197.
8. Grodstein F, Stampfer MJ, Manson JE, et al.: Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996, 335: 453-461.
9. Wren BG: The effect of oestrogen on the female cardiovascular system. Med J Aust 1992, 157: 204-208.
10. The Writing Group for the PEPI Trial: Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA 1995, 273: 199-208.
11. Hulley S, Grady D, Bush T, et al.: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 1998, 280: 605-613.
12. Stamler J: Blood pressure and high blood pressure. Aspects of risk. Hypertension 1991, 18: 95-107.
13. Tremollieres FA, Pouilles JM, Cauneille C, et al.: Coronary heart disease risk factors and menopause: a study in 1684 French women. Atherosclerosis 1999, 142: 415-423.
14. Wenger NK: Hypertension and other cardiovascular risk factors in women. Am J Hypertens 1995, 8: 94s-99s.
15. August P, Oparil S: Hypertension in women. J Clin Endocrinol Metab 1999, 84: 1862-1866.
16. Calhoun DA, Oparil S: High blood pressure in women. Int J Fertil Womens Med 1997, 42: 198-205.
17. Oparil S: Hypertension in postmenopausal women: pathophysiology and management. Curr Opin Nephrol Hypertens 1995, 4: 438-442.
18. Burt VL, Whelton P, Roccella EJ, et al.: Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey. Hypertension 1995, 25: 305-313.
19. Saltzberg S, Stroh JA, Frishman WH: Isolated systolic hypertension in the elderly: pathophysiology and treatment. Med Clin North Am 1988, 72: 523-547.
20. Franklin SS, Khan SA, Wong ND, et al.: Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham Heart Study. Circulation 1999, 100: 354-360.
21. Kannel WB: Historic perspectives on the relative contributions of diastolic and systolic blood pressure elevation to cardiovascular risk profile. Am Heart J 1999, 138: 205-210.
22. Franklin SS, Gustin W, Wong ND, et al.: Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation 1997, 96: 308-315.
23. Joint National Committee: The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997, 157: 2413-2446.
24. Weber MA, Julius S: The challenge of very mild hypertension: should treatment be sooner or later? Am J Hypertens 1998, 11: 1495-1496.
25. van den Hoogen PC, Feskens EJ, Nagelkerke NJ, et al.: The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. Seven Countries Study Research Group. N Engl J Med 2000, 342: 1-8.
26. MacMahon S: Blood pressure and the risk of cardiovascular disease. N Engl J Med 2000, 342: 50-52.
27. Yusuf S, Sleight P, Pogue J, et al.: The Heart Outcomes Prevention Evaluation Study Investigators: Effects of an angiotensinconvertingenzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction, and stroke in high risk patients. N Engl J Med 2000, 342: 145-153.
28. van Ittersum FJ, van Baal WM, Kenemans P, et al.: Ambulatory-not office-blood pressures decline during hormone replacement therapy in healthy postmenopausal women. Am J Hypertens 1998, 11: 1147-1152.
29. Seely EW, Walsh BW, Gerhard MD, et al.: Estradiol with or without progesterone and ambulatory blood pressure in postmenopausal women. Hypertension 1999, 33: 1190-1194.
30. Beljic T, Babic D, Marinkovic J, et al.: The effect of hormone replacement therapy on diastolic left ventricular function in hypertensive and normotensive postmenopausal women. Maturitas 1998, 29: 229-238.
31. Mercuro G, Zoncu S, Piano D, et al.: Estradiol-17 beta reduces blood pressure and restores the normal amplitude of the circadian blood pressure rhythm in postmenopausal hypertension. Am J Hypertens 1998, 11: 909-913.
32. Manhem K, Ahlm H, Milsom I, et al.: Transdermal oestrogen reduces daytime blood pressure in hypertensive women. J Hum Hypertens 1998, 12: 323-327.
33. Lip GY, Beevers M, Churchill D, et al.: Hormone replacement therapy and blood pressure in hypertensive women. J Hum Hypertens 1994, 8: 491-494.
34. Kornhauser C, Malacara JM, Garay ME, et al.: The effect of hormone replacement therapy on blood pressure and cardiovascular risk factors in menopausal women with moderate hypertension. J Hum Hypertens 1997, 11: 405-411.
35. Amorosa A, Garzia P, Ferri GM, et al.: Hypertension and menopausal syndrome: effects of hormone replacement therapy and antihypertensive drugs. Riv Eur Sci Med Farmacol 1996, 18: 149-152.
36. Schunkert H, Danser AH, Hense HW, et al.: Effects of estrogen replacement therapy on the renin-angiotensin system in postmenopausal women. Circulation 1997, 95: 39-45.
37. Nickenig G, Baumer AT, Grohe C, et al.: Estrogen modulates AT1 receptor gene expression in vitro and in vivo. Circulation 1998, 97: 2197-2201.
38. Hayakawa H, Raij L: The link among nitric oxide synthase activity, endothelial function, and aortic and ventricular hypertrophy in hypertension. Hypertension 1997, 29: 235-241.
39. Raij L: Nitric oxide, salt sensitivity, and cardiorenal injury in hypertension. Semin Nephrol 1999, 19: 296-303.
40. Mendelsohn ME, Karas RH: The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999, 340: 1801-1811.
41. Watson CS, Gametchu B: Membrane-initiated steroid actions and the proteins that mediate them. Proc Soc Exp Biol Med 1999, 220: 9-19.
42. Karas RH, Baur WE, van Eickles M, et al.: Human vascular smooth muscle cells express an estrogen receptor isoform. FEBS Lett 1995, 377: 103-108.
43. Imthurn B, Rosselli M, Jaeger AW, et al.: Differential effects of hormone-replacement therapy on endogenous nitric oxide (nitrite/nitrate) levels in postmenopausal women substituted with 17 beta-estradiol valerate and cyproterone acetate or medroxyprogesterone acetate. J Clin Endocrinol Metab 1997, 82: 388-394.
44. Hayashi T, Yamada K, Esaki T, et al.: Effect of estrogen on isoforms of nitric oxide synthase: possible mechanism of anti-atherosclerotic effect of estrogen. Gerontology 1997, 43: Suppl 1: 24-34.
45. Barbacanne MA, Rami J, Michel JB, et al.: Estradiol increases rat aorta endothelium-derived relaxing factor (EDRF) activity without changes in endothelial NO synthase gene expression: possible role of decreased endotheliumderived superoxide anion production. Cardiovasc Res 1999, 41: 672-681.
46. Chen Z, Yuhanna IS, Galcheva-Gargova Z, et al.: Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. J Clin Invest 1999, 103: 401-406.
47. MacRitchie AN, Jun. SS, Chen Z, et al.: Estrogen upregulates endothelial nitric oxide synthase gene expression in fetal pulmonary artery endothelium. Circ Res 1997, 81: 355-362.
48. Tominaga T, Suzuki H, Ogata Y, et al.: The role of sex hormones and sodium intake in postmenopausal hypertension. J Human Hypertens 1991, 5: 495-500.
49. Harrison-Bernard LM, Raij L: Post ovariectomy (OVX) hypertension (HTN) is linked to upregulation of renal angiotensin II type 1(AT1) receptors and increased salt-sensitivity (Abstract). Hypertension 1999, 34: 336.
50. Reckelhoff JF, Zhang H, Granger JP: Testosterone exacerbates hypertension and reduces pressure-natriuresis in male spontaneously hypertensive rats. Hypertension 1998, 31: 435-439.
51. Schnaper HW: Estrogen: it's not just for reproduction any more. Kidney Int 1999, 55: 1577-1579.
52. Kaplan NM: The treatment of hypertension in women. Arch Intern Med 1995, 155: 563-567.